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Abstract
Background: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for 
myelofibrosis (MI),  though  limited by a high rate  of transplant
the present study we evaluate the outcome of MI patients undergoi
reduced intensity conditioning (RIC) regimens, and the impact of prognostic factors. 
Design and methods: Fifty two patients were transplanted in 26 Italian centres between 1998 
and 2006. We analyzed the influence of patient and d
transplant  procedures  on  TRM  and  overall  survival  (OS)  by  means  of  univariate  and 
multivariate analyses.
Results: At  SCT,    median  age  was  52,5  years  (32
intermediate or high Dupriez score. Conditioning regimens were based on fludarabine plus 
busulphan in  27% of  patients, thiotepa  plus cyclophosphamide  in 46% and  miscellaneous 
drug combinations in the other 27% of cases. Stem cells came from matched sibling donors 
for 75% of the patients and mismatched sibling or unrelated donors for the remaining 25%. 
The cumulative incidence of engraftment at day 90 after transplant was 83% (95% CI, 0.87
0.97). The estimated 1-year TRM was 30%.  The estimated 3
and OS after hematopoietic SCT was 44%  and 38% respectively. 
higher leukocyte count and circulating blasts in the peripheral blood before SCT significantly 
reduced EFS and OS respectively. 
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Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for 
myelofibrosis (MI),  though  limited by a high rate  of transplant-related mortality (TRM).  In 
the present study we evaluate the outcome of MI patients undergoing an allogenic SCT after 
reduced intensity conditioning (RIC) regimens, and the impact of prognostic factors. 
: Fifty two patients were transplanted in 26 Italian centres between 1998 
and 2006. We analyzed the influence of patient and disease clinical features before SCT and of 
transplant  procedures  on  TRM  and  overall  survival  (OS)  by  means  of  univariate  and 
At  SCT,    median  age  was  52,5  years  (32-68)  and    89%  of  the  patients  had    an 
priez score. Conditioning regimens were based on fludarabine plus 
busulphan in  27% of patients,  thiotepa plus cyclophosphamide  in 46% and  miscellaneous 
drug combinations in the other 27% of cases. Stem cells came from matched sibling donors 
patients and mismatched sibling or unrelated donors for the remaining 25%. 
The cumulative incidence of engraftment at day 90 after transplant was 83% (95% CI, 0.87
year TRM was 30%.  The estimated 3-year event-free
OS after hematopoietic SCT was 44%  and 38% respectively. In multivariate analysis, an 
higher leukocyte count and circulating blasts in the peripheral blood before SCT significantly 
reduced EFS and OS respectively. 
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Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for 
related mortality (TRM).  In 
ng an allogenic SCT after 
reduced intensity conditioning (RIC) regimens, and the impact of prognostic factors. 
: Fifty two patients were transplanted in 26 Italian centres between 1998 
isease clinical features before SCT and of 
transplant  procedures  on  TRM  and  overall  survival  (OS)  by  means  of  univariate  and 
68)  and    89%  of  the  patients  had    an 
priez score. Conditioning regimens were based on fludarabine plus 
busulphan in  27% of patients,  thiotepa plus cyclophosphamide in  46% and  miscellaneous 
drug combinations in the other 27% of cases. Stem cells came from matched sibling donors 
patients and mismatched sibling or unrelated donors for the remaining 25%. 
The cumulative incidence of engraftment at day 90 after transplant was 83% (95% CI, 0.87-
free-survival (EFS) 
In multivariate analysis, an 
higher leukocyte count and circulating blasts in the peripheral blood before SCT significantly Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Interpretation  and  conclusions: We  conclude  that  the  extension  of  the  disease  before 
transplantation  based  on  the  presence  of  circulating  blasts  and  high  leukocyte  counts 
significantly affected the outcome after HSCT
Introduction:  Myelofibrosis  (MI)  is  a  clonal 
hematopoietic  stem  cell  disorder  that  is  clinically 
characterized  by  progressive  anemia,  marked 
splenomegaly,  extramedullary  hematopoiesis, 
constitutional  symptoms  and  a  significant  risk  of 
evolution into acute leukaemia. MI can appear as a 
primitive or idiopathic disorder or, less frequently, 
as  a  secondary  complication  of  essential 
thrombocythemia  or  polycythemia  vera,  with  a 
clinical  presentation  and  course  similar  to  the 
idiopathic form. The disease affects mainly elderly 
people, with a median age at diagnosis of about 65 
years.  It  is  a  heterogeneous  disorder  in  term  of 
presentation and evolution, with  a median overall 
survival  (OS)  varying  between  2  and  15  years, 
depending on the presence or absence of clinically 
defined  prognostic  factors.    Adverse  prognostic 
factors  for  survival  have  included  advanced  age, 
marked  anemia,  leukocytosis  or  leukopenia, 
abnormal  karyotype,  constitutional  symptoms  and 
presence  of  circulating  blasts    Moreover,  the 
prognostic  value  of  cytogenetic  abnormalities, 
increased  number  of  circulating  CD34+  cells  in 
peripheral  blood  and  JAK2  mutational  status  has 
been  also  evaluated.      The  available  prognostic 
score  systems  are  mainly  based  on  clinical 
variables.  The  most widely  used  is  the  Dupriez 
score
1,  which  is  based  on  hemoglobin  level  and 
leukocyte  count. The Mayo Clinic Group tried to 
improve  the  Lille  score  by  adding 
thrombocytopenia  and  monocytosis.
2 The 
International  Working  Group  for  Myelofibrosis 
Research  and  Treatment  (IWGMRT)  recently 
proposed  a  new  scoring  system  analyzing  the 
largest patient population and recognized 5   main 
unfavourable variables which were: age > 65 years, 
presence  of  constitutional  symptoms,  and 
circulating  blasts  cells  ≥  1%  ,  anemia  and  
leucocytosis.
3 All  these  prognostic  systems  could 
clearly separate  intermediate or high risk patients 
(with a median survival ranging between 1 and 4 
years)  from patients with a favourable prognosis 
(median survival of 8-10 years). 
Drug  therapy  is  aimed  at  alleviating  the 
symptoms,  and  has  not  been  shown  to  improve 
survival.  Allogeneic  hematopoietic  stem  cell 
transplantation (HSCT) is the only treatment with 
the potential for curing MI and has been performed 
in patients with unfavourable clinical variables for 
several  years. The  application  of  HSCT  in  MI  is 
strongly  limited  by  an  unacceptable  rate  of 
transplantation-related toxicity occurring in patients 
receiving  standard myeloablative  conditioninig. In 
fact,  transplant-related  mortality  (TRM)    ranged 
from  25  to  48%  in  different  studies.
4-9 The 
discovery  that  allogeneic  stem  cell  can  engraft 
patients  prepared  with  nonmyeloablative  doses  of 
radiochemotherapy  has  led  to  the  rapid 
development  of  a  variety  of  reduced-intensity 
conditioning  (RIC)  regimens  that  have  been 
successfully applied to patients with MI who would 
not be candidate for standard myeloablative HSCT 
due  to  advanced  age  or  co-morbidities.  RIC 
regimens might theoretically be applied to a large 
number  of  patients  with  an  older  age  and 
comorbidities, while  maintaining  the  potential  for 
eradicating the disease based on the graft-versus MI 
effect.
10-14 Studies in small  series of  patients who 
underwent RIC  HSCT demonstrated the feasibility 
of  the  procedure,  and  reported  encouraging  TRM 
rates  below 15%  and  OS  rates  around  80%. 
However, the patients included were a few and the 
follow-up  was  still  short.  RIC  regimens  were 
heterogeneous  and  included  fludarabine  plus  low 
dose  TBI  or  alkylating  agent  (busulfan  or 
melphalan). 
We have already published the analysis of the 
data  of  the  Gruppo  Italiano  Trapianto  Midollo 
Osseo  (G.I.T.M.O.)  Registry  regarding  a  total  of 
100  patients  with  MI,  who  underwent  allogeneic  
HSCT  in  26  different  Italian  Transplant  Centres 
between 1986 and 2005.
15 Herein we present a sub-
analysis  limited  to  the  patients  who  had  received 
RIC regimens in more recent years, with the aim of 
analysing  clinical  features  of  patients  and 
transplants  and  identifying    prognostic  factors 
affecting the outcome after HSCT.
Methods: Data were collected in an XLS database 
and imported into Stata/SE 9.0 for Windows for the 
statistical  analysis.    The  end-points  were 
engraftment,  acute  and  chronic  graft-versus-host 
disease  (GVHD),  relapse,  TRM,  overall  survival 
(OS) and event-free survival (EFS).  
TRM was defined as  death due to all causes not 
related  to  MI.    OS    was  defined  as  the  time 
(months) from date of transplant to either death or 
last observation. EFS was defined as the time from 
date  of  transplant  to    relapse,  death  or  last 
observation.  OS and EFS were described using the Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Kaplan-Meier  approach.  Analysis of  survival  was 
done using Cox proportional hazard models, after 
the  proportional  hazards  assumption  had  been 
verified.  All  variables  considered  in  univariate 
analysis  as  possible  prognostic  factors  were: 
primary  diagnosis  (primary  or  secondary  MI), 
Dupriez score  at  transplant  (low,  intermediate,  or 
high),  transplant  time  (before  and  after  2001), 
interval  between  diagnosis  and  transplantation 
(months),  transfusions  before  transplant, 
hemoglobin  levels,  leukocyte  cell  counts, 
circulating blasts, karyotype, previous splenectomy, 
splenomegaly  at  transplantation,  age  at 
transplantation, drugs of the conditioning regimen 
(fludarabine  plus  busulphan  or  thiotepa  plus 
cyclophosphamide  or  other  miscellaneous 
regimens),  source  of  stem  cells  (marrow  or 
peripheral blood), acute GVHD (grade 0-I or grade 
II-IV),  and  chronic  GVHD  (absent  or  limited  or 
extensive). Multivariate stepwise analyses included 
all variables significant at p0.10 in an univariate 
analysis. Retention in the stepwise model required  
the  variable  to  be  significant  at  p0.05  in  a 
multivariate analysis.
Results: A  total  of  52  patients  were 
transplanted between January 1998 and December 
2006.  (table  1  and  2).  Median  time  between 
diagnosis and HSCT was 13 months (1-161). At the 
time of HSCT, median age was 52,5 years (32-68), 
89% of the patients had a Dupriez score ≥ 1, 45% 
had previously received  red cells transfusions, 27% 
had  blasts  in  the  peripheral  blood,  22  %  had  an 
abnormal karyotype,  51% had splenomegaly, 43% 
underwent splenectomy before HSCT. Conditioning 
regimens were based on fludarabine plus busulphan 
in 27% of patients, thiotepa plus cyclophosphamide 
in 46% and miscellaneous drug combinations in the 
other 27% of cases.   Stem cells came from matched 
sibling  donors  for  75%  of  the  patients  and 
mismatched  sibling  or  unrelated  donors  for  the 
remaining 25%.  Thirty-five per cent received bone 
marrow  and  65%  peripheral  blood  stem  cells.  
Median  time  of  follow-up  after  HSCT  was  13 
months for the whole population and 34 months for 
surviving  patients.  Eighty-three  per  cent  achieved 
full engrafment. Eighteen patients developed acute 
GVHD grades II to IV for a cumulative incidence 
of38%  by  day  100  after  transplantation  (95%  CI 
0.9-1.3). Chronic GVHD occurred in 20 patients for 
a  cumulative  incidence  of  50%  at  2  years  (95% 
CI0.4-0.8):  it  was  limited  in  14  patients  and 
extensive in 6 patients. One-year TRM was 30%.  
The cumulative incidence of relapse was 19% at 1 
year.
Table  1:  Clinical  and  haematological  characteristics  of  the 
patients at allergeneic stem cell transplantation.
Total no. Patients 52
Age 
Median (range) 52,5 (32-68)
Diagnosis
Idiopathic   myelofibrosis 36/44 (82%)
Secondary  myelofibrosis 8/44(18%)
  
Time diagnosis-SCT ( months)
Median (range) 13 (1-162)
≤ 12 21/52 (40%)
13-35 14/52 (27%)
≥ 36 17/52 (33%)
Dupriez score at transplant
Low 5/44 (11%)
Intermediate 30/44 (68%)
High 9/44 (21%)
Previous transfusions 18/40 (45%)
Karyotype
Normal 28/36 (78%)
Abnormal 8/36 (22%)
Previous splenectomy 20/46 (43%)
Splenomegaly at transplant 22/43 (51%)
Circulating blasts at transplant 11/41 (27%)
Hemoglobin level at transplant (g/dl)
Median (range) 9.1 (5.6-14.4)
White cell count at transplant (x 10
6/l)
Median (range) 7.7 (0.6-118)
The estimated 3-year EFS and OS were respectively 
44%  and  38%.    In  univariate  analysis  factors 
associated with an higher TRM rate were: an older  
transplant  date  (1998-2000  vs  2001-2006: 
HR=0.25; CI95%[0.09;0.68]; p=0.007) and  presence 
of  grade II-IV acute GVHD (HR 2.42; CI95%[0.92-
6.38]; p=0.073), The final survival model did not 
show  any  significant  prognostic  factor  for  TRM. 
Prognostic  factors  that  were  significantlyMedit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 2: Transplant-related characteristics
Year of the transplant
1998-2000 8/52 (15%)
2001-2006 44/52  (85%)
Donor
HLA matched sibling 39/52 (75%)
Unrelated or  HLA  “mismatched” sibling 13/52 (25%)
Source 
Bone marrow 18/52 (35%)
Peripheral blood 34/52 (65%)
Conditioning regimen
Fludarabine plus busulphan 14/52 (27%)
Thiotepa plus cyclophosphamide 24/52 (46%)
Fludarabine- 2 Gy TBI 4/52 ( 8%)
Fludarabine-melphalan 6/52  (11%)
Other 4/52  (8%)
(p0.10)  associated  with  EFS  in  the  univariate 
proportional  hazards  model  were:  transplant  time 
(1998-2000  vs  2001-2006:  HR=0.46; 
CI95%[0.19;1.15]; p=0.098), leukocyte count before 
transplantation (HR=1.00002;  CI95%
[1.000002:1.000032];  p=0.028)  and  presence  of 
chronic  extensive  GVHD  (HR=0.27;  CI95%
[0.06;1.26]; p=0.095). In multivariate analysis only 
an  higher  leukocyte  count  before  HSCT  was 
significantly associated with an unfavourable EFS 
(HR=1.000028;  CI95% [1.000011:1.000045]; 
p=0.001). In univariate analysis factors that affected 
OS were: presence of  blasts in the peripheral blood 
before transplantation (HR=3.37; CI95%[0.36;2.39]; 
p=0.020),  an  higher  leukocyte  count  before 
transplantation  (HR=1.00002;  CI95%
[1.000002:1.000035]; p=0.032), an older  transplant 
date  (1998-2000  vs  2001-2006:  HR=0.32;  CI95%
[0.21;0.82];  p=0.018).  In  multivariate  analysis    
circulating  blasts  in  the  peripheral  blood  before 
transplantation  significantly  reduced  OS 
(HR=3.356; CI95%[1.21;9.34]; p=0.020). 
Discussion:  We  recently  reported  data  on  a 
population of 100 patients with MI who underwent 
allogeneic HSCT in 26 transplant centers that are 
part  of  the  GITMO  in  a  20-year  period  between 
1986 and 2006 and we retrospectively analyzed the 
influence  of  patient  and  disease  clinical  features 
before SCT and of transplant procedures on TRM 
and  OS.
15 We  confirmed  that  MI  remains  a  rare 
indication  for  SCT  with  the  recruitment  of  about 
15-17  cases  per  year  since  2002  and  observed  a 
great  heterogeneity  in  terms  of  conditioning 
regimens,  GHVD  prophylaxis  and  supportive 
measures.  Although    we  observed  a  significative 
and progressive  improvement of TRM after 1996, 
we could not recognized any significative difference 
in  outcome  either  between  patients  treated  with 
myeloablative versus RIC regimens or among those 
treated with  different  regimens. The lack of any 
association  between  intensity  of  conditioning  or 
type of drugs included in the preparative regimen 
could be in part due to the great heterogeneity of 
transplant  procedures.  The  present  analysis  is 
limited  to  the  patients  who  had  received  RIC 
regimens , with the aim of  identifying  prognostic 
factors  affecting  the  outcome  after  HSCT.  This 
study confirms  that outcome after RIC transplants 
has been progressively improved in the last decade. 
However,  transplant  toxicity  is  still  a  matter  of 
concern , since  we observed a 1- year TRM of 30% 
that  is    higher  than  that  reported  in  previously 
published  series  after  RIC  transplants  (4-6)  and 
similar  to  TRM  observed  after  myeloablative 
transplants.
10-14 The extension of the disease before 
transplantation based on the presence of circulating 
blasts  and  high  leukocyte  counts  significantly 
affected both EFS and OS after HSCT.  These two 
parameters  are  both  included  in  well-known 
prognostic scoring systems: the leukocyte count in 
the  Dupriez  score  and  the  circulating  blasts 
percentage  in  the  IWGMRT  one.  These  scoring 
systems,  that  were    validated  in  non-transplanted 
patients, have demonstrated to impact the outcome 
after the transplant, too. In our series of patients we 
could  not  identify  any  transplant  procedure 
(conditioning regimen or stem cell source or donor) 
influencing outcome, probably because of the small 
number of patients examined and the heterogeneity 
of  chemotherapy  and  immunosuppressive  drugs 
delivered. However, the most commonly used RIC 
regimen  was  the  association  of  thiotepa  and 
cyclophosphamide, that was administered to nearly 
half  of  the  patients.  Thiotepa  is  known  to  be  a 
radiomimetic  drug  with  a  potent  myeloablative 
activity  associated  with  an  immunosuppressive 
effect  and  minimal  toxicity.  The  combination  of 
thiotepa  and  cyclophosphamide  was  originally 
described for autologous transplants,
16 then it was 
incorporated  in  the  conventional  preparative 
regimens for T-cell depleted allogeneic SCT from 
HLA matched and haploidentical sibling donors.
17-18 
The Genova group reported that thiotepa at the dose Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 3. Summary of the previously reported clinical results of allogeneic stem cell transplantation following reduced-intensity-
conditioning  transplants in myelofibrosis.
of 15 mg/kg and cyclophosphamide  at the dose of 
120-150 mg/kg produced complete engraftment and 
remission  in  29  out  of  31  patients,  mostly  with 
advanced disease.
19 In a subsequent study, the same 
regimen with a 30% reduction of both drug doses 
was well tolerated by patients between 45 and 60 
years with advanced leukemias, although half of the 
patients  had  persisting  or  relapsing  disease.
20  The 
incorporation  of  thiotepa  in  RIC  regimens  have 
represented an innovation in several  Italian studies 
for  different  haematological  diseases:  thiotepa  in 
association  with  cyclophosphamide  and/or 
fludarabine  followed by haematopoietic stem cells 
have demonstrated high feasibility and effectiveness  
in  elderly  patients  with    acute  leukemias,
20  in 
heavily  pretreated  relapsed  or  refractory 
lymphomas
21 and in myelodisplastic syndromes.
22
How do our study results compare with those 
already reported? Table 3 summarized the clinical 
results of the studies published. Most of them were 
retrospective and include  small series of patients. 
The  largest  series  was  reported  by  Kroeger  on 
behalf  of  the  European  Group  for  Blood  and 
Marrow  Transplantation.
23  The  study was 
prospective and included 104 patients mainly with 
intermediate  or  high  risk  score  who  received  a 
conditioning  regimen  based  on  fludarabine  180 
mg/mq and busulfan 8 mg/kg i.v or 10 mg/Kg p.o 
and hematopoietic stem cells coming from sibling 
or unrelated donors. Engraftment was 99%; 1-year 
TRM was 16% and was significantly increased in 
patients  older  than  50  years,  in  cases  with  
intermediate and high-risk MI and after transplants 
from mismatched donors .  Five-year OS was 67% 
and 5 –year EFS was 51%. Relapse rate was higher 
in splenectomized patients and if disease duration 
prior  transplant  was  >  24  months.  Moreover, 
Kroeger  reported  that  this  conditioning  regimen 
induced  a  JAK-2  negativity  in  78%  of  patients 
carrying  the  V617-JAK2  mutation  before 
transplant
24  and  produced  a rapid regression of 
bone  marrow  fibrosis  in  59%  of  patients  al  day 
+100  and  in  100%  of  patients  at  day  +360.
25  At 
present, the busulfan-fludarabine regimen could be 
considered as the RIC regimen that has been tested 
on the largest patient population and demonstrated 
the best results in terms of feasibility and clinical, 
molecular and histological responses.
The  largest  single  center  experience  was 
reported  by  Bacigalupo  et  al,
26  concerning  46 
patients who had received a RIC regimen based on 
thiotepa and cyclophosphamide. TRM was 24% and 
5-year OS was 45% in the whole population, but it 
ranged  from  8%  to  77%  according  to  the  risk 
category.  One of the most important contributions 
of  these recent studies is  the identification of  the 
Rondelli
10 Synder 
12 Merup 
14 Kroger 
23 Bacigalupo 
26 Present
GITMO series
N° pts 21 9 10 103 46 52
Median age 54 (27-68) 54 (46-68) 40 (5-63) 51 (24-67) 55 (32-68) 52 (32-68)
RIC 
Conditioning
Fluda + busulfan
Thiotepa+cy
Fluda+
melphalan
Fluda + TBI
Fluda+
Melphalan
Fluda + TBI
Fluda+ busulfan
Fluda+Cy+
melphalan
Fluda + 
busulfan
Thiotepa + cy
±melphalan
Fluda +  busulfan
Thiotepa + cy
Donor 
REL/UNREL 19/2 2/7 20/7 33/70 32/14 39/13
Median
follow-up 
survivors
31 months 32 months 50 months 33 months 39 months 34 months
1 y-TRM % 9% 44% 29% 16% 24% 30% ( at 1 y)
3y- OS % 78% (at 2 y) 56% 70% 67% (at 5 y) 45% (at 5 y) 44% (at 3 y)
3 y -relase 9% 0% Not evaluable 22 % 19% 19%Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
prognostic factors that influence the outcome after 
HSCT.  Among  the  transplant-related  variables,  
transplants  from  unrelated  donors  had  a 
significative worse OS in comparison with sibling 
transplants in the Italian series
15 and in the Genova 
study,
26  while  in  the  German  study
23 only 
mismatched unrelated donors had an unfavourable 
impact on OS. Among the disease-related variables, 
Dupriez score identified significative differences in 
the outcome after SCT in the German study,
23 while 
Bacigalupo
26 recognized    large  splenomegaly  and 
higher  than  20  red  cell  transfusions    before 
transplant as powerful unfavourable predictors for 
OS.  Role  of  splenectomy  is  still  a  controversial 
issue. Patients with large splenomegaly at transplant 
can have a slower granulocyte and platelet recovery, 
an  higher  risk  of  graft  failure  or  persistence  of 
splenomegaly for several months after transplant.
27-
28  However, splenectomy    is associated of  a 25% 
rate of bleeding and thrombotic complications and 
6%  perioperative  deaths  in  patients  with 
myelofibrosis.
29 The increased risk of relapse after 
transplant  in  splenectomized  patients  observed  in 
the German study  was not confirmed in other series 
of  patients.  Since  splenectomy  is  commonly 
performed in patients with larger splenomegaly, it 
can be hypothesized that splenectomy could be an 
indirect  sign  of  a  greater  extension  of  the 
myeloproliferative  disease  before  transplant,  that  
could be associated to an higher risk of relapse after 
HSCT.
Conclusions:  In  conclusion, these results indicate 
that allogeneic SCT may be an attractive treatment 
approach for patients with high-risk MI. Although 
the outcome has been significantly improved in the 
last decade due to the reduction of TRM, several 
issues such as the timing of HSCT, the  choice of 
the conditioning regimen, the source of stem cells, 
and  the donor type have not been fully understood.   
Prospective studies that will explore new transplant 
modalities with   the aims  of  reducing TRM and 
allow  MI  long-term  control  are  warranted  in  this 
setting. The  GITMO  will  promote  a  prospective 
study  comparing  two  RIC  regimes,  fludarabine-
busulfan  versus  fludarabine-thiotepa  in  patients 
with high-risk MI.
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